Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Hygieia Raises Funds for siRNA Portfolio

publication date: Sep 4, 2024

Hangzhou Hygieia Biotech completed an A2 financing to advance its 11 siRNA molecules, including a portfolio of three clinical stage candidates. The company said the round raised “tens of millions of yuan.” In a previous A1 round, completed in July, the company booked almost $14 million (100 million yuan), in a funding led by Tasly Pharma. With very little venture capital, Hegieia has already moved to partnership stage on two of its assets, one with Shanghai Fosun and the other with Tasly. The company is currently working on an A+ round for additional funds to support clinical trials. The A2 round was led by Huangpu Biotechnology Fund, with Nanwan Baiao Fund participating. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here